アラジール症候群（ALGS）の治療におけるTAK-625の研究

基本情報

NCT ID

NCT05543174

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

7

治験依頼者名

Takeda

概要

The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future. The participants will be treated with TAK-625 for up to the end of study (about 34 months). Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)